Cosentyx (secukinumab) is a biologic drug that is used to treat autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to Drug Patent Watch [1], Cosentyx was first approved by the FDA in 2015 and is currently under patent protection until 2031. The drug works by targeting and blocking the activity of a protein called interleukin-17A, which is involved in the inflammatory response that causes these diseases.

A study published in the Journal of Clinical and Aesthetic Dermatology [2] found that Cosentyx is generally well-tolerated by patients with psoriasis, with few serious adverse events reported. The most common side effects reported in clinical trials include upper respiratory tract infections, diarrhea, and injection site reactions. However, the study notes that long-term safety data for Cosentyx is limited, and further research is needed to fully understand the potential risks and benefits of the drug.

The latest guidelines from UpToDate [3] recommend Cosentyx as a first-line treatment option for moderate to severe plaque psoriasis, based on its efficacy and safety profile. The guidelines note that Cosentyx has been shown to be effective in improving skin clearance and quality of life in patients with psoriasis, and that it has a favorable safety profile compared to other biologic drugs used to treat psoriasis.

In summary, while there is limited long-term safety data available for Cosentyx, current research suggests that it is generally well-tolerated by patients with psoriasis and has a favorable safety profile compared to other biologic drugs. The drug is recommended as a first-line treatment option for moderate to severe plaque psoriasis, and ongoing research will continue to monitor for any potential new complications.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923940/
[3] https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults